AC
ACET.O
—
NASDAQ
Biotechnology & Medical Research
Adicet Bio Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
86,4M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-73,4 %
Net margin
—
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$8,33
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Adicet Bio Inc is a clinical-stage biotechnology company focused on the development of novel cell therapies for the treatment of cancer, leveraging its proprietary cell engineering platform to enhance the efficacy and safety of T cell-based immunotherapies.
Business. Adicet Bio Inc (ACET.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY7 analysts
7 buy0 hold0 sell
Avg 12m price target53,00
Analyst recommendations
7 analysts · consensus BuyBuy7
Hold0
Sell0
12-month price target
53,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
7 analysts · indicative
Ownership→
Franklin Advisers, Inc.
largest disclosed fund holder
Profitability→
-73,4 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ACET.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Adicet Bio Inc (ACET.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDAdicet Bio Inc maintains a strong liquidity position, with a current ratio of 7.47 and cash and equivalents of $38.9 million, which is significantly higher than the industry median. The company's price-to-book ratio of 0.49 suggests that the market values the company at a discount to its book value, which may reflect the high-risk nature of its clinical-stage operations.
The company's profitability metrics are negative, with a return on equity of -73.36% and a return on assets of -60.72%, indicating that it is not currently generating returns for shareholders or asset holders. These figures are in line with the typical performance of clinical-stage biotechnology firms, which often operate at a loss during the development phase.
Adicet Bio Inc's revenue is not disclosed in the provided data, and the company does not report segment or geographic revenue breakdowns. As a clinical-stage company, its operations are likely concentrated in the United States, where the majority of its research and development activities are conducted.
The company's growth trajectory is speculative, as it has not yet generated positive net income or operating income. The outlook for the current fiscal year does not provide specific numeric deltas, but the company's ongoing clinical trials and partnerships may influence its future revenue potential.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.01 suggests minimal leverage, and the absence of long-term debt further supports its low financial risk profile.
Recent events include the publication of clinical trial results and the initiation of new trials, which are critical for the company's development pipeline. Analysts have provided a wide range of price targets, from $18 to $128, with a mean recommendation of 1.57, indicating a generally positive outlook despite the company's current financial losses.
Key takeaways
- Adicet Bio Inc has a strong liquidity position with a current ratio of 7.47 and $38.9 million in cash and equivalents.
- The company is not currently profitable, with a return on equity of -73.36% and a return on assets of -60.72%.
- Adicet Bio Inc's valuation is at a discount to book value, as indicated by a price-to-book ratio of 0.49.
- The company's growth is speculative, with no current revenue and a focus on clinical-stage development.
- Analysts have provided a wide range of price targets, from $18 to $128, with a mean recommendation of 1.57.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$9,24
Market cap
$78.6M
Enterprise valueⓘ
$40.7M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.5x
P / Tangible bookⓘ
0.5x
Tangible book
$159.2M
Net cashⓘ
$37.9M
Current ratioⓘ
7.5
Debt / equityⓘ
0.0
ROAⓘ
-60.7%
ROEⓘ
-73.4%
Cash conversionⓘ
82.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-9,10
Predicted surprise
+0,00
Beat probability
45 %
Analysts
7
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -9,10 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -133,9M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution7 analysts
Strong buy3
Buy4
Hold0
Sell0
Strong sell0
12-month price target$53,00 · Median $26,00
Low $18,00High $128,00
Operating income · consensus-133,9M USD
EPS surprise
−86,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$18,00
Mean$53,00
Median$26,00
High$128,00
Spot$9,24
+473.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-73,4 %Bottom quartile
D/E0,01Above median
Cash Conv0,82Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 085 587 sh13 grants12 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 4 200 @ $8,10grant · 2026-06-21
- Director · Stock Option (Right to Buy) → Common StockAcquired 4 200 @ $8,10grant · 2026-06-21
- Director · Stock Option (Right to Buy) → Common StockAcquired 4 200 @ $8,10grant · 2026-06-21
- Director · Stock Option (Right to Buy) → Common StockAcquired 4 200 @ $8,10grant · 2026-06-21
- Director · Stock Option (Right to Buy) → Common StockAcquired 4 200 @ $8,10grant · 2026-06-21
- Director · Stock Option (Right to Buy) → Common StockAcquired 4 200 @ $8,10grant · 2026-06-21
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 55 000 @ $8,10grant · 2026-06-19
- Director, President & CEO · Stock Option (Right to Buy) → Common StockAcquired 55 000 @ $8,10grant · 2026-06-19
- 10% owner · Pre-Funded Warrant (Right to Buy) → Common StockAcquired 250 000 @ $0,00other · 2026-04-27
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 72 555 @ $6,81grant · 2026-03-25
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 72 555 @ $6,81grant · 2026-03-25
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 43 361 @ $6,81grant · 2026-03-25
- Director, President & CEO · Stock Option (Right to Buy) → Common StockAcquired 468 555 @ $6,81grant · 2026-03-25
- Chief Technology Officer · Stock Option (Right to Buy) → Common StockAcquired 43 361 @ $6,81grant · 2026-03-25
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- Adicet Bio Inc Market data — financials · 2026-05-27
- Adicet Bio Inc Market data — analyst estimates · 2026-05-27
- Adicet Bio Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2024-06-300,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Chen SchorPresident, Chief Executive Officer, Director
Insider activity
Net buying5 buys · 4 sellsnet $5,9M6 insiders · last 365d
- 10% owner · Common StockOther 250 000 · 2026-04-27
- 10% owner · Common StockSold 32 523 @ $6,29$205K · 2026-04-08
- 10% owner · Common StockSold 40 416 @ $6,52$264K · 2026-04-08
- 10% owner · Common StockSold 2 400 @ $6,38$15K · 2026-04-07
- 10% owner · Common StockSold 29 319 @ $6,53$191K · 2026-04-07
- 10% owner · Common StockBought 74 751 @ $7,27$543K · 2026-02-20
- 10% owner · Common StockBought 74 268 @ $7,21$535K · 2026-02-19
- 10% owner · Common StockBought 74 577 @ $7,04$525K · 2026-02-18
- Director, President & CEO · Common StockOther 1 755 @ $8,44$15K · 2026-01-24
- Chief Scientific Officer · Common StockOther 535 @ $8,44$5K · 2026-01-24
- Chief Technology Officer · Common StockOther 535 @ $8,44$5K · 2026-01-24
- Chief Financial Officer · Common StockOther 546 @ $8,44$5K · 2026-01-24
- 10% owner · Common StockBought 1 500 000 @ $1,00$1,5M · 2025-10-08
- 10% owner · Common StockBought 3 500 000 @ $1,00$3,5M · 2025-10-08
Short positioning
383.2Kshares short-24.2% vs prior
4.29days to cover
28.6%short of daily vol
21fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ACET.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -73.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 4.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -60.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -3.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 0.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -31.1%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 55.5%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.21xDerived (calculated)
- Current ratio (FY 2025-12-31): 7.47xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -0.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -14.7%Derived (calculated)
- Shareholders' equity (annual): USD 159.21MSEC XBRL filing
- Cash & equivalents (annual): USD 38.92MSEC XBRL filing
- Operating income (annual): USD -122.11MSEC XBRL filing
- Capex (annual): USD 1.74MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -17SEC XBRL filing
- R&D expense (annual): USD 99.13MSEC XBRL filing
- Interest expense (annual): USD 36KSEC XBRL filing
- Pre-tax income (annual): USD -116.8MSEC XBRL filing
- Total liabilities (annual): USD 33.15MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-21 00:00 UTCINSIDER8 insider transactions — 2026-06 8 derivative
2026-06-21INSIDERSinclair Andrew acquired 4.2k sh Stock Option (Right to Buy) — Director
2026-06-21INSIDERChodakewitz Jeffrey acquired 4.2k sh Stock Option (Right to Buy) — Director
2026-06-21INSIDERDUBIN STEVE acquired 4.2k sh Stock Option (Right to Buy) — Director
2026-06-21INSIDERKlickstein Lloyd acquired 4.2k sh Stock Option (Right to Buy) — Director
2026-06-21INSIDERPeng Katie acquired 4.2k sh Stock Option (Right to Buy) — Director
2026-06-21INSIDERGrissinger Michael acquired 4.2k sh Stock Option (Right to Buy) — Director
2026-06-19INSIDERAftab Blake acquired 55.0k sh Stock Option (Right to Buy) — Chief Scientific Officer
2026-06-19INSIDERSchor Chen acquired 55.0k sh Stock Option (Right to Buy) — Director, President & CEO
2026-04-27 00:00 UTCINSIDER6 insider transactions — 2026-04 · net sell $675k 1 derivative
2026-04-27INSIDERRA CAPITAL MANAGEMENT, L.P. transacted 250.0k sh — 10% owner
2026-04-27INSIDERRA CAPITAL MANAGEMENT, L.P. acquired 250.0k sh Pre-Funded Warrant (Right to Buy) — 10% owner
2026-04-08INSIDERORBIMED ADVISORS LLC sold 32.5k sh — 10% owner ~$205k
2026-04-08INSIDERORBIMED ADVISORS LLC sold 40.4k sh — 10% owner ~$264k
2026-04-07INSIDERORBIMED ADVISORS LLC sold 29.3k sh — 10% owner ~$191k
2026-04-07INSIDERORBIMED ADVISORS LLC sold 2.4k sh — 10% owner ~$15k
2026-03-25 00:00 UTCINSIDER5 insider transactions — 2026-03 5 derivative
2026-03-25INSIDERSchor Chen acquired 468.6k sh Stock Option (Right to Buy) — Director, President & CEO
2026-03-25INSIDERMaltzman Julia D. acquired 72.6k sh Stock Option (Right to Buy) — Chief Medical Officer
2026-03-25INSIDERHealey Don acquired 43.4k sh Stock Option (Right to Buy) — Chief Technology Officer
2026-03-25INSIDERAftab Blake acquired 72.6k sh Stock Option (Right to Buy) — Chief Scientific Officer
2026-03-25INSIDERHarvey Brian Nicholas acquired 43.4k sh Stock Option (Right to Buy) — Chief Financial Officer
2026-02-20 00:00 UTCINSIDER3 insider transactions — 2026-02 · net buy $1.6M
2026-02-20INSIDERRA CAPITAL MANAGEMENT, L.P. bought 74.8k sh — 10% owner ~$543k
2026-02-19INSIDERRA CAPITAL MANAGEMENT, L.P. bought 74.3k sh — 10% owner ~$535k
2026-02-18INSIDERRA CAPITAL MANAGEMENT, L.P. bought 74.6k sh — 10% owner ~$525k
2026-01-24 00:00 UTCINSIDER4 insider transactions — 2026-01
2026-01-24INSIDERHarvey Brian Nicholas transacted 546 sh — Chief Financial Officer ~$5k
2026-01-24INSIDERHealey Don transacted 535 sh — Chief Technology Officer ~$5k
2026-01-24INSIDERSchor Chen transacted 1.8k sh — Director, President & CEO ~$15k
2026-01-24INSIDERAftab Blake transacted 535 sh — Chief Scientific Officer ~$5k
Showing the 40 most recent of 49 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage